Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D5C4YE
|
|||
| Drug Name |
PR-006
|
|||
| Drug Type |
Gene therapy
|
|||
| Indication | Frontotemporal dementia [ICD-11: 6D83] | Phase 1/2 | [1] | |
| Company |
Prevail Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Progranulin (PGRN) | Target Info | . | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04408625) A Phase 1/2 Ascending Dose Study to Evaluate the Safety and Effects on Progranulin Levels of LY3884963 in Patients With Fronto-Temporal Dementia With Progranulin Mutations (FTD-GRN). U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Prevail Therapeutics | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.